Polina Liss
Internal Medicine · New York, NYNPI 1225002009
Payments from drug & device makers
Across 197 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$606
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$506
- Amgen$430
- Boehringer Ingelheim$311
- Pfizer$236
- Sumitomo Pharma America, Inc.$195
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,15898%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $606 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $506 |
| Amgen | 19 | $430 |
| Boehringer Ingelheim | 10 | $311 |
| Pfizer | 12 | $236 |
| Sumitomo Pharma America, Inc. | 11 | $195 |
| Exact Sciences | 8 | $178 |
| Astellas Pharma US Inc | 6 | $176 |
| Idorsia Pharmaceuticals US Inc | 7 | $131 |
| Axsome Therapeutics, Inc. | 6 | $126 |
| Novo Nordisk | 6 | $119 |
| Acella Pharmaceuticals, LLC | 5 | $108 |
| Intra-sana Laboratories | 4 | $101 |
| KCI USA, Inc. | 2 | $96 |
| Radius Health, Inc. | 4 | $96 |
| Lilly USA, LLC | 4 | $94 |
| IBSA Pharma Inc. | 4 | $80 |
| Bausch Health US, LLC | 3 | $68 |
| Shire North American Group Inc | 3 | $62 |
| UCB, Inc. | 2 | $57 |
| Novartis | 2 | $56 |
| Eisai Inc. | 3 | $50 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| Phadia US Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $43 |
| AstraZeneca | 2 | $41 |
| Genentech USA, Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $25 |
| Bristol Myers Squibb | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
How this compares
$4,223 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $50,717 |
| Metformin Er GastricMetformin Hcl | 11 | $49,242 |
| OzempicSemaglutide | 30 | $39,815 |
| EliquisApixaban | 24 | $20,825 |
| Diclofenac Sodium | 26 | $19,962 |
| Repatha SureclickEvolocumab | 28 | $18,542 |
| CreonLipase/Protease/Amylase | 17 | $17,353 |
| VascepaIcosapent Ethyl | 20 | $16,658 |
| MounjaroTirzepatide | 12 | $12,199 |
| Repatha SyringeEvolocumab | 19 | $10,656 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $9,503 |
| TrintellixVortioxetine Hydrobromide | 14 | $8,374 |
| Armour ThyroidThyroid,pork | 87 | $7,598 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $6,636 |
| MyrbetriqMirabegron | 13 | $5,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $311 | $50,71744 claims |
| Novo NordiskOzempic | $119 | $39,81530 claims |
| AbbVieCreon, Armour Thyroid, Synthroid | $606 | $27,311136 claims |
| PfizerEliquis | $236 | $20,82524 claims |
| Lilly USA, LLCMounjaro | $94 | $12,19912 claims |
| Astellas Pharma US IncMyrbetriq | $176 | $5,73013 claims |
| IBSA Pharma Inc.Tirosint | $80 | $4,84314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.